Eli Lilly’s Foundayo Shines in Sleep Apnea Trial; Big Tech Rallies on Analyst Upgrades

By / / Breaking News

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • Eli Lilly (LLY) reported that its oral obesity drug Foundayo (orforglipron) reduced sleep apnea severity by up to 43.8% in a 52-week Phase 3 trial.
  • Amazon (AMZN) and Meta Platforms (META) shares surged 5.5% and 4.5% respectively following bullish sentiment from JPMorgan, which named them top internet picks.
  • Senator Chris Van Hollen has reportedly entered "active listening mode" regarding a potential challenge to Chuck Schumer for Senate Democratic leadership.
  • Alphabet (GOOGL) shares gained 3.2% as the broader mega-cap tech sector rebounded, despite being removed from JPMorgan's Analyst Focus List in favor of Meta.

Eli Lilly’s Foundayo Meets Primary Endpoints in Sleep Apnea Study

Eli Lilly (LLY) announced breakthrough results from its ATTAIN-OSA Phase 3 clinical trial, demonstrating that its oral GLP-1 receptor agonist, Foundayo, significantly improves outcomes for patients with obstructive sleep apnea (OSA). At the 52-week mark, participants not using positive airway pressure (PAP) therapy saw a mean reduction of 21.1 events per hour on the Apnea-Hypopnea Index (AHI), representing a 43.8% improvement from baseline.

The study, presented at the American Heart Association (AHA) Scientific Sessions 2026, also highlighted significant secondary benefits. Participants experienced an average weight loss of approximately 11% and a reduction in systolic blood pressure by up to 8.6 mmHg. Following these results, Eli Lilly (LLY) confirmed plans to submit Foundayo for FDA approval in the OSA indication by the end of 2026.

Big Tech Rallies as JPMorgan Shifts Focus to Meta and Amazon

Mega-cap technology stocks saw a significant boost on Monday, led by a 5.5% jump in Amazon (AMZN) and a 4.5% rise in Meta Platforms (META). The rally was largely attributed to JPMorgan updating its Analyst Focus List, where it identified Meta and Amazon as its preferred internet sector picks for the remainder of the year.

While Alphabet (GOOGL) climbed 3.2%, it was notably removed from JPMorgan’s focus list. Analysts cited Meta’s superior near-term earnings momentum and AI-driven advertising gains as the primary reason for the rotation. Despite the removal, the bank maintains an Overweight rating on Alphabet, noting its continued growth in cloud and AI infrastructure.

Leadership Shakeup Looms in the U.S. Senate

In the political sphere, Senator Chris Van Hollen (D-MD) is reportedly considering a run against Senate Minority Leader Chuck Schumer. According to sources familiar with his thinking, Van Hollen has received an "outpouring of calls" and is currently in an active listening phase regarding a leadership bid.

Van Hollen, a leading progressive voice, has signaled that he requires specific commitments from Schumer regarding the party's legislative agenda before offering his support for another term. This development comes amid broader discussions within the Democratic caucus following the 2026 midterm elections, where some members have called for a "new generation" of leadership.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top